Rovaldi Christopher 4
4 · Keros Therapeutics, Inc. · Filed Feb 19, 2025
Insider Transaction Report
Form 4
Rovaldi Christopher
Chief Operating Officer
Transactions
- Award
Common Stock
2025-02-18+60,000→ 60,000 total
Footnotes (1)
- [F1]Represents a restricted stock unit ("RSU") award. The RSUs vest as follows: 33% of the RSUs shall vest on February 17, 2026, an additional 34% of the total number of RSUs shall vest on August 15, 2026, and the remaining 33% of the total number of RSUs shall vest on February 16, 2027, in each case, subject to the Reporting Person's Continuous Service (as defined in the 2020 Plan) through each applicable vesting date.